ArticleOncotarget2017

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.

Weiran Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.